hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06370143 id: 24-083 briefTitle: A Study Collecting Health Information to Understand and Prevent Gastric Cancer overallStatus: RECRUITING date: 2024-04-11 date: 2036-04-11 date: 2036-04-11 date: 2024-04-17 date: 2024-04-17 name: Memorial Sloan Kettering Cancer Center class: OTHER briefSummary: The purpose of this study is to create a registry of participants with precursor lesions for gastric cancer, including gastric atrophy, intestinal metaplasia, and dysplasia. Normal controls and individuals with gastric cancer for comparison of baseline characteristics will also be enrolled. conditions: Gastric Atrophy conditions: Gastric Intestinal Metaplasia conditions: Dysplasia conditions: Gastric Adenocarcinoma conditions: Gastric Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 3200 type: ESTIMATED name: Questionnaire measure: Creation of participant registry sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) status: RECRUITING city: Basking Ridge state: New Jersey zip: 07920 country: United States name: Monika Laszkowska, MD role: CONTACT phone: 212-639-6857 lat: 40.70621 lon: -74.54932 facility: Memorial Sloan Kettering Monmouth (All Protocol Activities) status: RECRUITING city: Middletown state: New Jersey zip: 07748 country: United States name: Monika Laszkowska, MD role: CONTACT phone: 212-639-6857 lat: 40.39652 lon: -74.09211 facility: Memorial Sloan Kettering Bergen (Limited Protocol Activities) status: RECRUITING city: Montvale state: New Jersey zip: 07645 country: United States name: Monika Laszkowska, MD role: CONTACT phone: 212-639-6857 lat: 41.04676 lon: -74.02292 facility: Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) status: RECRUITING city: Commack state: New York zip: 11725 country: United States name: Monika Laszkowska, PhD role: CONTACT phone: 212-639-6857 lat: 40.84288 lon: -73.29289 facility: Memorial Sloan Kettering Westchester (Limited Protocol Activities) status: RECRUITING city: Harrison state: New York zip: 10604 country: United States name: Monika Laszkowska, MD role: CONTACT phone: 212-639-6857 lat: 40.96899 lon: -73.71263 facility: Memorial Sloan Kettering Cancer Center (All protocol activites) status: RECRUITING city: New York state: New York zip: 10065 country: United States name: Monika Laszkowska, MD role: CONTACT phone: 212-639-6857 lat: 40.71427 lon: -74.00597 facility: Memorial Sloan Kettering Nassau (Limited Protocol Activites) status: RECRUITING city: Rockville Centre state: New York zip: 11553 country: United States name: Monika Laszkowska, MD role: CONTACT phone: 212-639-6857 lat: 40.65871 lon: -73.64124 hasResults: False
nctId: NCT06370130 id: AerospaceCH briefTitle: Different Dose of Esketamine Inhibiting Response to Laryngeal Mask Airway Insertion overallStatus: COMPLETED date: 2022-05-01 date: 2022-12-20 date: 2023-03-10 date: 2024-04-17 date: 2024-04-17 name: Aerospace Center Hospital class: OTHER briefSummary: Objective To prospectively determine the median effective dose (ED50) of propofol for inhibiting a response to laryngeal mask airway (LMA) insertion when combined with different doses of esketamine in female patients.
Methods Fifty-eight female patients (aged 20-60, ASAⅠ-Ⅱ) scheduled for elective hysteroscopy were enrolled and randomly divided into two groups, one administered 0.2 mg/kg of esketamine (K1 group, n = 28) and the other 0.3 mg/kg of esketamine (K2 group, n = 30). The two groups received the corresponding doses of esketamine intravenously, followed by an intravenous injection of propofol (injection time was 30 s). The initial dose of propofol was 2 mg/kg, and the dose ratio of propofol in the adjacent patients was 0.9. If there was a positive reaction to LMA insertion, the dose ratio in the next patient was increased by one gradient, and if not, the dose ratio was decreased by one gradient. The median effective dose (ED50), 95% effective dose (ED95) and 95% confidence interval (95%CI) of propofol for inhibiting a response to LMA insertion in the two esketamine groups were calculated using a probit analysis. conditions: Anesthesia studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 58 type: ACTUAL name: Esketamine 0.2mg/kg name: Esketamine 0.3mg/kg measure: Record of the patient response during LMA placement measure: Overall condition of LMA placement measure: Record related indicators measure: Record related indicators measure: Record related indicators measure: Record related indicators measure: Record of additional doses of propofol and the adverse reactions of positive patients during the induction process (hypotension, bradycardia and apnoea, etc.) sex: FEMALE minimumAge: 20 Years maximumAge: 60 Years stdAges: ADULT facility: Liang-Yuan Lu city: Beijing state: Beijing zip: 100049 country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06370117 id: Aydın Adnan Menderes briefTitle: The Effects of Three Different Nonpharmacological Methods Used During Vascular Access in Children on Pain and Anxiety overallStatus: COMPLETED date: 2023-02-01 date: 2023-10-30 date: 2023-12-30 date: 2024-04-17 date: 2024-04-17 name: Aydin Adnan Menderes University class: OTHER briefSummary: The research was conducted to evaluate the effects of three different non-pharmacological methods (playing a music video, buzzy application, listening to a music video + buzzy application) on the pain and anxiety levels of children in the 4-12 age group during vascular access.
H0.3. Listening to a music video + applying buzzy during the vascular access procedure has no effect on children's pain and anxiety levels. conditions: Pain conditions: Anxiety conditions: Nurse's Role studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: It is a randomized controlled experimental study. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 126 type: ACTUAL name: Buzzy name: Music video listening name: Buzzy+ Music video listening measure: Wong-Baker Facial Expression Rating Scale measure: Children's Fear and Anxiety Scale sex: ALL minimumAge: 4 Years maximumAge: 12 Years stdAges: CHILD facility: Bircan Kahraman Berberoğlu city: Aydın state: AYDIN-efeler zip: 0900 country: Turkey lat: 37.84501 lon: 27.83963 hasResults: False
nctId: NCT06370104 id: NL85041.018.23 briefTitle: Treating Suicidality Remotely acronym: TREASURE overallStatus: NOT_YET_RECRUITING date: 2024-04-25 date: 2028-04-25 date: 2028-04-25 date: 2024-04-17 date: 2024-04-17 name: 113 Suicide Prevention class: OTHER name: Amsterdam UMC briefSummary: Background: Practical and psychological barriers make it difficult for people with Suicidal Thoughts and Behaviors (STBs) to get professional help. Online interventions have the potential to overcome many of these barriers, but the online interventions to date have produced small or short-lived effects and have only been found to reduce suicidal thoughts, not behaviors. This is a crucial limitation, since previous studies have shown that interventions that reduce suicidal thoughts often do not prevent suicide attempts, and vice versa.
Methods: A fully remote randomized controlled trial will be conducted in which 364 participants of 16 years and older will be recruited through the website of a suicide prevention helpline in the Netherlands and randomized with an allocation ratio of 1:1 to either Brief Cognitive Behavioral Therapy for Suicide Prevention (BCBT-SP) or a semi-guided online self-help course that has previously been found superior to waitlist in reducing suicidal thoughts. The primary outcome of the study is the number of suicide attempts, measured with the Columbia Suicide Severity Rating Scale. Secondary outcomes are self-reported suicidal ideation, healthcare utilization, treatment satisfaction, adverse effects, and quality of life. All outcomes will be assessed at baseline, immediately after the treatment and at 18 months follow-up.
Discussion: If remote BCBT-SP proves effective, the findings of this study will add to the evidence base of BCBT-SP as one of very few psychological interventions with replicated effectiveness in preventing suicide attempts and provide the first evidence to date that remote interventions cannot only reduce suicidal thoughts, but also prevent suicidal behavior. conditions: Suicide Attempt studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel randomized controlled trial with a 1:1 allocation ratio. primaryPurpose: PREVENTION masking: SINGLE maskingDescription: Participants are not blind to the treatment condition, but are unaware which is the experimental condition and which the control condition. whoMasked: OUTCOMES_ASSESSOR count: 364 type: ESTIMATED name: Brief Cognitive Behavioral Therapy for Suicide Prevention name: Living under control measure: Number of suicide attempts measure: Severity of suicidal ideation measure: Severity of suicidal Thoughts and Behaviors Composite measure: Treatment satisfaction measure: Adverse effects measure: Co-occuring mental health issues measure: Quality of life sex: ALL minimumAge: 16 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: 113 Suicide Prevention city: Amsterdam state: Zuid-Holland zip: 1105BP country: Netherlands name: Wilco Janssen, MSc role: CONTACT phone: 020 3 113 883 email: w.janssen@113.nl name: Saskia Mérelle, PhD role: CONTACT phone: 020 3 113 883 email: s.merelle@113.nl lat: 52.37403 lon: 4.88969 hasResults: False
nctId: NCT06370091 id: PICVII19-41 briefTitle: Effect of Xylitol-based Chewing Gums, Sugar-free and Sugared, on Salivary Flow and pH in Young Adults overallStatus: RECRUITING date: 2023-12-12 date: 2024-05-31 date: 2024-07-31 date: 2024-04-17 date: 2024-04-24 name: Universidad Católica de Cuenca class: OTHER briefSummary: This study was planned to evaluate the effects of xylitol-based chewing gums, sugar-free and sugared, on salivary flow and pH in young adults. conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: It will be an experimental study through a double-blind parallel randomized controlled trial.
All saliva samples will be collected using the spitting method. Each participant will provide a basal saliva sample for 5 minutes. Participants must meet the following inclusion criteria: having at least 20 teeth, providing written informed consent, and being willing to comply with the study procedures. The exclusion criteria will include individuals with systemic, infectious, or inflammatory diseases or those taking medications, antibiotics, or fluoride in the last month; regular consumers of products and mouthwashes containing xylitol or sorbitol, with abnormal salivary flow (\<1 ml/min), pregnant women or those on contraceptive pill treatment, or with abnormal dietary habits; subjects with periodontal disease or presence of dental caries primaryPurpose: OTHER masking: DOUBLE maskingDescription: Participants who meet the selection criteria will be probabilistically assigned using simple random sampling through a lottery system. An urn will be used to draw colors corresponding to a type of chewing gum whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 100 type: ESTIMATED name: Gum of Xylitol name: Gum of sugar free name: Gum of sugar name: Paraffin wax measure: G1: Gum of xilytol measure: G2: Gum of sugar free measure: G3: Gum of sugar measure: G4: Parafinn wax sex: ALL minimumAge: 18 Years maximumAge: 25 Years stdAges: ADULT facility: Miriam Lima status: RECRUITING city: Cuenca state: Azuay zip: 010101 country: Ecuador name: Miriam Lima, Ph D role: CONTACT phone: 0999975073 email: mlimai@ucacue.edu.ec lat: -2.90055 lon: -79.00453 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-12-12 uploadDate: 2024-04-13T10:26 filename: Prot_000.pdf size: 1132158 hasResults: False
nctId: NCT06370078 id: Ahmed Helal briefTitle: Effect of Early Administration of Albumin 20% Versus Crystalloid overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-11-01 date: 2025-11-15 date: 2024-04-17 date: 2024-04-17 name: Egymedicalpedia class: INDUSTRY briefSummary: Sepsis and septic shock are global health problems, leading to a high mortality rate. They are often associated with extremely low blood pressure and multiple organ dysfunctions, which are the main causes of death in critically ill patients. Fluid resuscitation is one of the most critical treatments for patients with sepsis and septic shock.
An early administration of an appropriate fluid to patients is considered the most effective way to increase blood pressure, improve tissue perfusion, and save their lives. Crystalloid fluids are a subset of intravenous solutions composed of mineral salts and other small, water-soluble molecules, including normal, isotonic or hypertonic saline, and various buffered solutions. conditions: Septic Shock studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 46 type: ESTIMATED name: Albumin Human measure: Recovery from shock sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Assuit University hospitals city: Assiut country: Egypt name: Ahmed Abdelhamed Helal Mohamed, MSc role: CONTACT phone: +201140415513 email: Ahmedel3oksh@gmail.com name: Amany Hassan Abdelwahab, Assist.Prof. role: CONTACT phone: +201004610623 email: Amanihassan1976@yahoo.com name: Noha Yahia Mohamed, Lecturer role: PRINCIPAL_INVESTIGATOR lat: 27.18096 lon: 31.18368 hasResults: False
nctId: NCT06370065 id: HLX10IIT70-TJ briefTitle: Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients overallStatus: RECRUITING date: 2023-04-27 date: 2024-06-30 date: 2024-12-31 date: 2024-04-17 date: 2024-04-17 name: Tianjin Medical University Cancer Institute and Hospital class: OTHER briefSummary: Evaluation of the efficacy and safety of Serplulimab combined with bevacizumab biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) patients conditions: Advanced Hepatocellular Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 35 type: ESTIMATED name: HAIC+Serplulimab（HLX10）+ Bevacizumab Biosimilar（HLX04） measure: ORR measure: PFS measure: OS sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tianjin Cancer Hospital Airport Hospital status: RECRUITING city: Tianjin state: Tianjin country: China name: Huikai Li, MD role: CONTACT lat: 39.14222 lon: 117.17667 hasResults: False
nctId: NCT06370052 id: CHCRI-DJ-HS briefTitle: Pathophysiological Basis of Hidradenitis Suppurativa overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-12-31 date: 2026-12-31 date: 2024-04-17 date: 2024-04-17 name: Clinical Hospital Center Rijeka class: OTHER briefSummary: HS is a chronic inflammatory disease manifested by recurrent inflammatory nodules, abscesses and tunnels under the skin. This disease is characterized by an inflammatory process that takes place in hair follicles, sebaceous glands and surrounding tissue. Because of its frequent recurrence and chronicity, it represents a major public health problem and there is a need for better diagnosis and new and more effective drugs. This research can be a part of realizing the stated needs. conditions: Hidradenitis Suppurativa studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: excision measure: The pathohistological changes measure: The expression of cytokines measure: The correlation of the clinical Hurley classification and pathohistological changes sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06370039 id: INV-102-CS-003 briefTitle: Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease overallStatus: RECRUITING date: 2024-03-27 date: 2024-08 date: 2024-08 date: 2024-04-17 date: 2024-04-24 name: Invirsa, Inc. class: INDUSTRY briefSummary: Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during 4-week repeat dosing in subjects with moderate to severe dry eye disease. conditions: Dry Eye Disease studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 110 type: ESTIMATED name: INV-102 name: Vehicle measure: Change from Baseline in corneal fluorescein staining total score on the National Eye Institute (NEI)/Industry scale measure: Percentage of eyes with complete clearing of central corneal fluorescein staining sex: ALL minimumAge: 18 Years maximumAge: 74 Years stdAges: ADULT stdAges: OLDER_ADULT facility: iuvo BioScience status: RECRUITING city: Rush state: New York zip: 14543 country: United States lat: 42.9959 lon: -77.64556 hasResults: False
nctId: NCT06370026 id: KSD-101-CR004 briefTitle: KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-12-31 date: 2026-12-31 date: 2024-04-17 date: 2024-04-17 name: Sun Yat-sen University class: OTHER name: Kousai Bio Co., Ltd. briefSummary: The main purpse of this study is to evaluate the safety of KSD-101 in patients with EBV-associated Nasopharyngeal Carcinoma,to evaluate the initial clinical outcomes and evaluate the immune response to KSD-101 for the treatment in Patients with EBV-associated Nasopharyngeal Carcinoma. conditions: Nasopharyngeal Carcinoma studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: KSD-101 measure: The incidence Adverse events (Safety endpoint) measure: EBV-DNA load measure: Objective response rate (ORR) measure: Disease control rate (DCR) measure: Duration of response (DOR) measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Levels of EBV-specific CD8+ T cells measure: Levels of B cells measure: Levels of NK cells measure: According to EORTC QLQ-C30 measure: According to EQ-5D-5L measure: According to EORTC QLQ-H&N35 measure: According to ECOG fitness status sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Yat-sen University Cancer Center city: Guangzhou state: Guangdong zip: 510060 country: China lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06370013 id: TT00420US14 briefTitle: Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors overallStatus: AVAILABLE date: 2024-04-17 date: 2024-04-17 name: TransThera Sciences (Nanjing), Inc. class: INDUSTRY briefSummary: This study is an open-label, multicenter study for Continued Characterization of Safety and Tolerability of TT-00420 (tinengotinib) Tablet Monotherapy in Adult Patients with Advanced Solid Tumors conditions: Advanced Solid Tumors conditions: Cholangiocarcinoma studyType: EXPANDED_ACCESS name: Tinengotinib sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University of Chicago Medical Center status: AVAILABLE city: Chicago state: Illinois zip: 60637 country: United States lat: 41.85003 lon: -87.65005 facility: Roswell Park Comprehensive Cancer Center status: AVAILABLE city: Buffalo state: New York zip: 14203 country: United States lat: 42.88645 lon: -78.87837 facility: Sarah Cannon Research Institute status: AVAILABLE city: Nashville state: Tennessee zip: 37203 country: United States lat: 36.16589 lon: -86.78444 facility: MD Anderson Cancer Center status: AVAILABLE city: Houston state: Texas zip: 77030 country: United States lat: 29.76328 lon: -95.36327 facility: UW Carbone Cancer Center status: AVAILABLE city: Madison state: Wisconsin zip: 53705 country: United States lat: 43.07305 lon: -89.40123 hasResults: False
nctId: NCT06370000 id: MCC-23-20817 id: HM20029540 type: OTHER domain: Virginia Commonwealth University briefTitle: Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality acronym: REMAIN1 overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2026-10-31 date: 2028-10-31 date: 2024-04-17 date: 2024-04-17 name: Virginia Commonwealth University class: OTHER briefSummary: Test feasibility of an oral maintenance strategy for transplant eligible AML patients in first CR who are medically underserved or have a disadvantage in the CDC SDOH domains conditions: Acute Myeloid Leukemia studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: Oral Azacitidine measure: Rate of completion of at least 4 cycles an oral maintenance strategy for transplant eligible AML patients in CR who are medically underserved or have a disadvantage in the CDC SDOH domains measure: Overall survival (OS) measure: Leukemia Free Survival (LFS) 3 months after beginning of treatment and at relapse, completion of treatment or removal from study measure: Measure rates of measurable residual disease (MRD) negativity sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Virginia Commonwealth University city: Richmond state: Virginia zip: 23298 country: United States name: Kristin Lantis, MSN, RN role: CONTACT phone: 804-828-2177 email: kllantis@vcu.edu name: Massey Heme Malig Team role: CONTACT email: MasseyHemMlg@vcu.edu name: Keri Maher, DO role: PRINCIPAL_INVESTIGATOR lat: 37.55376 lon: -77.46026 hasResults: False
nctId: NCT06369987 id: 46238 briefTitle: Visual Performance of Dailies Total1 Multifocal and Acuvue Oasys Max 1-Day Multifocal in Presbyopic Lens Wearers acronym: GIRAFFE overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-10 date: 2024-10 date: 2024-04-17 date: 2024-04-17 name: University of Waterloo class: OTHER name: Alcon Research briefSummary: The purpose of this study is to measure the logMAR visual acuity when presbyopic soft lens wearers are fit with Dailies Total1 Multifocal and ACUVUE OASYS MAX 1-DAY Multifocal. conditions: Presbyopia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 40 type: ESTIMATED name: Deleficon A (multifocal) name: Senofilcon A (multifocal) measure: High contrast visual acuity (logMAR) at 6m measure: High contrast visual acuity (logMAR) at 40cm sex: ALL minimumAge: 42 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre for Ocular Research & Education (CORE) city: Waterloo state: Ontario zip: N2L 3G1 country: Canada name: Jill Woods, MSc, MCOptom role: CONTACT phone: 519-888-4567 phoneExt: 36746 email: jwoods@uwaterloo.ca name: Lyndon Jones, PhD, FCOptom role: PRINCIPAL_INVESTIGATOR lat: 43.4668 lon: -80.51639 hasResults: False